Bausch Health Names Hedge Fund Billionaire Paulson Chairman [Business News Network (BNN) (Canada)]
Bausch + Lomb Corporation (BLCO)
Company Research
Source: Business News Network
The pharmaceutical and device company, which focuses on eye care, gastroenterology and dermatology products, said Papa's resignation wasn't the result of “any dispute or disagreement.” Paulson, who is also the company's second-largest shareholder, starts immediately. Shares of Bausch jumped in late trading, gaining about 3% to $7.49 a share at 6:30 p.m. in New York. The Canadian company was once known as Valeant Pharmaceuticals. It rebranded in 2018 in the wake of public outcry over drug price hikes and the conviction of a former executive for accepting a bribe. Its shares have been falling this year, declining more than 70% by Thursday's close, partly driven by the suspension of a planned spinoff of its skin-care business. That's much steeper than the 16% drop in the Dow Jones Industrial Average over the same period. The company spun off its eye-care unit, Bausch + Lomb Corp., earlier this year. “We have made progress towards the separation of Bausch + Lomb,” Paulson said in a
Show less
Read more
Impact Snapshot
Event Time:
BLCO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLCO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLCO alerts
High impacting Bausch + Lomb Corporation news events
Weekly update
A roundup of the hottest topics
BLCO
News
- Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes [Yahoo! Finance]Yahoo! Finance
- Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry EyesBusiness Wire
- Bausch + Lomb Co. (NYSE: BLCO) had its price target lowered by analysts at Royal Bank of Canada from $20.00 to $18.00. They now have an "outperform" rating on the stock.MarketBeat
- Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs [Yahoo! Finance]Yahoo! Finance
BLCO
Earnings
- 2/21/24 - Beat
BLCO
Sec Filings
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- BLCO's page on the SEC website